AstraZeneca completes purchase of Sumitomo Chemical’s stake in AstraZeneca K.K.
26 March 2014 | By AstraZeneca
AstraZeneca today announced it has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
26 March 2014 | By AstraZeneca
AstraZeneca today announced it has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K...
24 March 2014 | By AstraZeneca
AstraZeneca announced that the Japanese Ministry of Health, Labour and Welfare approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets)...
20 March 2014 | By AstraZeneca
AstraZeneca announced that Ann Cairns will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting on 24 April 2014...
3 March 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has approved the BYDUREON® Pen 2 mg as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes...
26 February 2014 | By AstraZeneca
AstraZeneca announced the FDA approved orphan drug MYALEPT™ , which is indicated as an adjunct to diet as replacement therapy for the treatment of complications of leptin deficiency in patients with congenital or acquired generalised lipodystrophy...
6 February 2014 | By AstraZeneca
"As expected, our financial performance for 2013 reflects the ongoing impact from the loss of exclusivity for several key brands..."
3 February 2014 | By AstraZeneca
AstraZeneca announced that it completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance...
22 January 2014 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb announced that Xigduo™ has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union...
16 January 2014 | By Bristol-Myers Squibb
Three-year commitment provides significant support for new generation of diabetes researchers...
14 January 2014 | By AstraZeneca
At the conference, Pascal Soriot will provide an update on the company’s development pipeline and outline its strategic priorities for 2014...
13 January 2014 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced the FDA approved FARXIGA™ (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus...
8 January 2014 | By AstraZeneca
Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology...
19 December 2013 | By AstraZeneca
Global agreement strengthens AstraZeneca’s commitment to diabetes, a key growth platform in a core strategic area for the company...
17 December 2013 | By
AstraZeneca is aware of reports that an 505(b)(2) NDA esomeprazole strontium product has been launched in the US by Hanmi Pharmaceutical and affiliates...
In this Screening In-Depth Focus: Technological and sociological advances in HTS: evolution and revolution?; Flow cytometry as a drug screening platform; Show Preview: High-Content Analysis 2014